CALT

Calliditas Therapeutics AB (publ) (CALT) | Rumor.io

Calliditas Therapeutics AB (publ)

CALT

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about CALT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

May 28

Asahi Kasei Corporation has made a takeover bid for Calliditas Therapeutics AB (publ) at SEK 416 per ADS, equivalent to approximately USD $39.37 in cash per ADS.
The deal is valued at around $1 billion and has been unanimously recommended by the Board of Calliditas Therapeutics AB.
The company's stock has seen significant price movements, with a 75% pre-market increase following the announcement of the takeover bid.

Generated by AI

Sentiment

Of the messages about CALT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +9.52
Bearish	—	—	—	0% -9.52

Bullish· Dec 20

Analyst HC Wainwright raises price target for Calliditas Therapeutics to $62, maintaining a buy rating.
The company's recent FDA approval of a billion-dollar drug pipeline is expected to positively impact stock price.
Calliditas Therapeutics stock has the potential to reach $399 in a year, making it a long-term investment opportunity.

Bearish· Dec 16

The FDA's approval of Calliditas Therapeutics AB (publ) ($CALT) may be questioned due to weak endpoints and exorbitant pricing.
The stock's slow movement is testing investors' patience, with potential for further downside and a possible touch of $22 or lower.
The company's prospects are bleak, with some investors expecting the stock to slow bleed back into the teens like the rest of the biotech sector.

Generated by AI

Topics

Of the messages about CALT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	0%
Macro	—	—	—	49.34%
Earnings	—	—	—	1.24%
Controversies	—	—	—	0.04%
Announcements	—	—	—	0.08%
Analysts	—	—	—	49.29%

May 28

Calliditas Therapeutics AB (publ) has received a takeover bid from Asahi Kasei Corporation, with a total equity value of about SEK 11.8 billion.
The acquisition offer includes a cash payment of SEK 416 per American Depositary Share (ADS), and the acceptance period is expected to commence on or around July 18 and expire on or around August 30.
Asahi Kasei has reserved the right to waive certain conditions for completion of the offer, and the board of Calliditas Therapeutics has unanimously recommended that shareholders accept the public tender offer.

Generated by AI

Community

Of the messages about CALT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	38.53%
Newcomers	—	—	—	61.47%

Also Discussed

Investors talking about CALT also mention

#	Name	Attention
1	Aquestive Therapeutics Inc.AQST	0%+0
2	BeyondSpring Inc.BYSI	0%0
3	Society Pass IncorporatedSOPA	0%0
4	ALLK - Allakos Inc.	——
5	Verrica Pharmaceuticals Inc.VRCA	0%0
6	SGMA - SigmaTron International, Inc.	——
7	Biofrontera Inc.BFRI	0%0
8	BioMarin Pharmaceutical IncBMRN	0%+0
9	Travere Therapeutics Inc.TVTX	0%0
10	Longeveron Inc. Class A Common StockLGVN	0%0